Unlike familial CEBPA-mutated AML, wherein AML development appears to be the principal clinical feature, other inherited cancer syndromes associated with HHMs and hematopoietic phenotypes also confer solid tumor risk. This evidence concerns the gene CEBPA and acute myeloid leukemia.